AI Signal Dashboard
Last updated: 04.13 01:58
Top Undervalued
+31.5¢
(No)
Arbitrage Opportunity
30¢
Arbitrage
59.9%
Annualized yield
FDA approves Retatrutide this year? AI analysis: • +31.5¢ undervalued • 59.9% arbitrage APY • Live Prediction Market fair value & mispricing alerts.
Arbitrage Plan:
Buy Option_'No'
Plan Description:
This is a typical soft arbitrage opportunity. Due to the strict and time-consuming FDA approval proc...
🔓 Unlock Full Arb Plan (Pro)
Undervalued Options Insights:
Based on healthcare forecasts and clinical trial timelines, most of Retatrutide's Phase 3 trials (TR...
🔓 Unlock Mispricing Insights (Pro)
Real-time High Yield Opportunities
View MoreAll
Outcomes
Market
Price
AI Fair
Value
Value
Edge
YesNo
33.5¢
66.5¢
2¢
98¢
0¢
+31.5¢
⚠️ Risk Warning: Live data may lag! Prices can shift instantly due to news or low liquidity. Before trading, use AI Chat for [Live Recalculate], [Check Liquidity], [Trollbox Radar], or review [Fair Value Logic] to verify.
Hedging
NVO
LLY
This event is a core catalyst for Eli Lilly (LLY). Retatrutide is viewed as the superior next-gen successor to Zepbound. An approval within 2026 (implying successful trials and expedited review) would significantly boost LLY's valuation premium. Conversely, a CRL (rejection) or delay would force a correction in high-growth expectations, triggering a significant pullback. Competitor Novo Nordisk (NVO) would also experience volatility due to shifting competitive dynamics.
Divergence
There is a significant divergence between the market price (Yes 30%) and the consensus among pharmaceutical experts. Mainstream medical analysis anticipates Retatrutide's earliest approval in 2027. Retail traders in the prediction market are overestimating the speed of FDA approval following the release of clinical trial results, ignoring the months-long standard review cycle required for a New Drug Application.